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Drug Price Quintuples,
Does Not Invoke Federal "March-In" Protections
By Zachary Ziliak
The National Institute of Health announced
inhibitor.
Aug. 4 that it would not authorize generic competiWith daily ritonavir dosage thus falling from
tion for Abbott Laboratories' AIDS drug Norvir, also
1200 mg to roughly 100 mg, Abbott responded in
known as ritonavir. Essential Inventions, a not-forDecember 2003 by quintupling the price of Norvir.
profit consumer advocacy group, had petitioned the
Essential Inventions, together with members of
NIH to grant such authorization after Abbott
Congress, including Rep. Sherrod Brown (D-Ohio),
increased the price of a daily dose of Norvir from
asked the NIH to exercise its Bayh-Dole "march-in"
$1.71 to $8.57.
rights, arguing that at its new price point, Norvir was
Essential Inventions based its request on the
no longer available to the public on reasonable
Bayh-Dole Act of 1981, which clarifies control rights
terms.
over inventions resulting fromdailyritonavirdos
public-private partnerships.m Between 1988 and 1993, Abbott received almost
Under
Bayh-Dole,
firms
receiving federal research $3.5 million from the NIH to assist with its
funding retain title over resultpublic n reto
ing inventions.2 However, ther
funding agency may "march the virus that
in" and force the patent-holder
to issue licenses to other companies to ensure the practical application of the
invention and its availability to the public on reasonable terms. 3
Between 1988 and 1993, Abbott received
almost $3.5 million from the NIH to assist with its
research into protease inhibitors to fight HIV, the
virus that causes AIDS. Protease is an enzyme that
HIV needs in order to infect new cells; protease
inhibitors block the protease enzyme. Abbott's
research led to the development of ritonavir. The
FDA approved ritonavir for widespread treatment of
HIV in 1996, and Abbott now markets ritonavir under
the brand name Norvir. "The whole relationship and
how it led to the discovery can be viewed as a BayhDole success story," said Abbott spokeswoman
Jennifer Smoter.
Abbott originally marketed ritonavir as a
stand-alone HIV drug with dosages of up to 1200
mg per day. However, later studies revealed that
ritonavir impeded the metabolism of various other
protease inhibitors, thereby extending their half-lives
in the body. As a result, HIV patients now commonly rely on drug "cocktails" consisting of 50 mg to 200
mg of ritonavir and a larger dose of another, less
noxious protease inhibitor. The ritonavir "booster"
improves the effectiveness of the primary protease

causes AIDS.
After taking statements from advocates on
both sides, the NIH ruled that Abbott had indeed
"met the standard of achieving practical application
of the applicable patents." More generally, the NIH
stated that Bayh-Dole should not be used to monitor
pricing. Such concerns would more properly be
addressed to the Federal Trade Commission.
Robert Weissman, general counsel for Essential
Inventions, announced that the organization would
appeal the decision.
In its request to the NIH, Essential Inventions
contended that the Norvir price increase would
directly affect consumers. Robert Huff of Gay Men's
Health Crisis, a not-for-profit group aimed at reducing the spread of HIV, called the Norvir price
increase "an egregious example of changing the
price on something and making it unaffordable to a
lot of people."
Abbott responded that both before and after
the price increase, Norvir's daily cost was the lowest
of any protease inhibitor on the market. Still, some
questioned Abbott's comparison, noting that Norvir
was more expensive than other protease inhibitors if
taken at its stand-alone dose. On June 10, 2004,
the FDA's Division of Drug Marketing, Advertising
and Communication called Abbott's argument "misNorvir, continued on page 17
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N orvir, continued from page 16
leading" for that reason.
Abbott further asserted that no patients
would actually pay more for Norvir than before
December 2003. Abbott froze the price of Norvir for
government AIDS programs and committed to giving
Norvir free to all patients not covered by insurance
or a government program.
Smoter reported a fast start to Abbotts
Patient Assistance Program. "We've been able to
process hundreds of applications this year already,"
she said.
GMHC's Huff acknowledged that the Norvir
Patient Assistance Program reduced the harm to

patients. "We're still looking for individual patients
who have been directly denied, and we haven't
found them, so it seems to be working," he said.
Huff, however, remained concerned about the delay
in processing applications for the Patient Assistance
Program. "For AIDS, you can't go two weeks without
your druas," he said.

Essential Inventions also argued that
Norvir's price increase could harm patients indirectly by reducing the incentive for companies to
research drugs that must be used in combination
with ritonavir. As Huff explained, the price hike "really sent a chill through some drug development programs from other companies. There's no point
developing a drug that depends on Norvir."
To mitigate such effects, Abbott froze the
price of Norvir for companies researching protease
inhibitors for use with ritonavir. However, the freeze
expires when the new protease inhibitors gain FDA
approval. Thus, research costs would not be affected, but the market price of the cocktail would still
rise. "Adding Norvir to what they want to charge will
make this just astronomical," said Huff.
Finally, Essential Inventions questioned
Abbott's pricing of Kaletra, an all-in-one protease
inhibitor cocktail. Like other cocktails, Kaletra consists of a primary protease inhibitors, lopinavir,

together with a smaller dose of ritonavir as a booster. However, as lopinavir and ritonavir are very similar chemically, Abbott claims that their interplay
exceeds that of other cocktails.
Abbott decided to leave the price of Kaletra
unchanged while increasing the price of Norvir.
Essential Inventions called Abbott's decision anticompetitive. It argued that patients who preferred a
different primary protease inhibitor would now have
to pay more for their ritonavir booster, while those
using lopinavir would incur no price increase. By
bundling lopinavir with ritonavir, Abbott was attempting to leverage its ritonavir monopoly into control
over the primary protease inhibitor market, Essential
Inventions said.
Abbott rejected Essential Inventions' link
between Kaletra and Norvir. "We didn't change the
price of Kaletra, because the use of that drug has
not changed," explained Smoter. Moreover, the
hypothesized shift to Kaletra has not materialized,
with Kaletra's market share remaining unchanged
over the past three quarters.
Such observations struck a chord with some
groups that had earlier questioned Kaletra's price.
Despite a letter from Senators Charles Schumer (DN.Y.), John McCain (R-Ariz.), and Ernest Hollings
(D-S.C.) requesting an antitrust investigation, the
FTC decided not to study the Norvir-Kaletra pricing
issue, Abbott reported recently.
Others, however, continue to raise questions. The attorneys general of New York and Illinois
both declared their intention to investigate the matter.
Essential Inventions' Weissman cautioned
that since switching protease inhibitors can shorten
the time they remain effective, patients generally
stick with one as long as it works. Weissman thus
predicted a gradual increase in Kaletra's market
share as patients come off their old drugs and have
to pick a new one. "It might not happen immediately, as there are serious consequences to bouncing
around among treatments," he said. "As people do
switch because they burn through the regimen and
become infected, the pricing decision is certainly
going to have an impact."
GMHC's Huff likewise predicts that "we
haven't seen all the impact of this yet."
The Norvir controversy exemplifies a longstanding policy debate surrounding Bayh-Dole.
Producers of generic drugs lobby for more zealous
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marching in by the government. If federal agencies
never act, they argue, recipients of federal research
grants will be free to impose monopoly prices on
consumers. Pharmaceutical researchers counter
that federal
funds represent a tiny
percentage

of the cost
required

to

bring a drug

Absent explicit pricing language in the law,
Essential Inventions and its supporters urged the
NIH to interpret the "reasonable terms" test to
include price. Weissman maintained that any other
interpretation
would undermine
goals
of
the
Bayh-Dole. "It's

Abbott froze the price of Norvir for
government AIDS programs and hard to imagine
what reasonable
6
t all terms means if it
*
d t giving orvir*re*

to market. In con
itted
tv
the case of
for
Norvir,
instance, the
NIH
contributed $3.5
million
to
Norvir's development compared to more than $300
million from Abbott. Research firms argue that if one
percent of federal funding suffices to undermine a
company's patent protection, firms will stop applying
for federal grants.
Because one of the primary goals of the
Bayh-Dole Act is "to encourage maximum participation ... in federally supported research and development efforts,"4 the NIH has preferred to err on the
side of caution. To date, neither the NIH nor any
other federal agency has ever curtailed a research
firm's patent protection by marching in. "You don't
want to kill the golden goose," said Joseph Allen,
president of the National Technology Transfer
Center.
Much of the debate leading up to the NIH's
decision concerned Bayh-Dole's use as a tool to
police pricing. In an article not specifically addressing Norvir, Professors Peter Arno and Michael Davis
pointed to several extracts from the Congressional
debates over Bayh-Dole that appeared to target
price regulation.5 In their words, "Congress's concern with march-in rights focused exclusively on
maintaining competitive conditions, controlling profits, and doing so through price control." 6
However, former Sen. Birch Bayh (D-Ind.),
one of the original sponsors of the law, told the NIH
that the law was aimed at ensuring companies
would develop inventions, not at allowing the government to set prices. GMHC's Huff acknowledged
that march-in advocates could not hang their hats on
explicit statutory language. A provision for price
controls "was not written into the final form, because
it probably wouldn't have passed," said Huff.
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doesn't include
price," Weissman

said. Huff added,
"If you
think
what
about
potential barriers

are to access,
price definitely can be included as a barrier. I think
they could have stretched it."
Pharmaceutical companies feared such
price controls, especially absent clear legislative
backing. Only a very small portion of the drugs that
companies research receive FDA approval, they
argued, and revenues from those few success stories must fund research in many more compounds.
"We have to make sure we realize the value of the
drugs we have on the market today, so that we can
develop future generations of medicines," said
Abbott's Smoter.
The Bayh-Dole Act grants patent-holders the
right to appeal decisions to the U.S. Court of Federal
Claims.7

While the act provides for no appeal of

rejection of march-in petitions beyond the funding
agency, Essential Inventions and Rep. Brown have
asked the Dept. of Health and Human Services to
review the NIH's decision.
"It is difficult to conceive of more unreasonable terms than a 400 percent price increase jerryrigged to stifle competition and imposed only on one
set of consumers-American consumers," Brown
wrote.
1. 35 U.S.C. §§ 200-212 (2004).
2. § 202(a).
3. §§ 201(f), 203(1)(a).

4. 35 U.S.C. § 200.
5. Peter S. Arno & Michael H. Davis, Why Don't We Enforce
Existing Drug Price Controls?, 75 Tul. L. Rev. 631, 662-66
(2001).
6. Id at 659.
7. 35 U.S.C. § 203(2).
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